Tenax Therapeutics, Inc.

NASDAQ:TENX

Biotechnology

Healthcare
$1.91 +0.88%

+$0.10 today

Market cap
$50.66M
Beta
0.97
P/E (TTM)
-9.4
EPS (TTM)
-$1.28
52W Low $5.34High $18.38

Volume 0.70M

Average 0.62M

Returns on capital

Tenax Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-54.2%

avg -231.5%

ROIC

-58.1%

avg -203.6%

ROA

-50.5%

avg -147.7%

Analysis

ROA is currently the strongest return metric at -50.5% versus its period average of -147.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Christopher T. Giordano

Chief Executive Officer, President & DirectorUSD 813.63K51——

Stuart Rich

Chief Medical Officer & DirectorUSD 490.22K76250.00K1.45%

Thomas A. McGauley

Principal Financial Officer & Principal Accounting OfficerUSD 475.5K53——

So-Young Kim

Executive Vice President of Clinical Development & Strategy————

Douglas Hay

Executive Vice President of Regulatory Affairs————

Doug Randall

Chief Business Officer————

Thomas R. Staab

Chief Financial Officer—58——

Timothy G. Healey

Chief Commercial Officer—60——

Compensation is shown in the reported currency; data updated Oct 3, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 9, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

18

$5.04M

Sells

0

$0.00

Net Transaction Value

+$5.04M

Net buying

Most Active

ADAR1 Capital Management, LLC

7 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 16, 26

Doogan Declan

Direct

Buy$101.8K
Sep 15, 26

Giordano Christopher Thomas

Direct

Buy$8.8K
Sep 11, 26

Giordano Christopher Thomas

Direct

Buy$11.3K
Sep 11, 26

STAAB THOMAS R II

Direct

Buy$11K
Sep 3, 26

ADAR1 Capital Management, LLC

Indirect

Buy$1.6M
Sep 2, 26

ADAR1 Capital Management, LLC

Indirect

Buy$337.6K
Sep 1, 26

ADAR1 Capital Management, LLC

Indirect

Buy$321.6K
Aug 31, 26

ADAR1 Capital Management, LLC

Indirect

Buy$722.6K
Aug 24, 26

ADAR1 Capital Management, LLC

Indirect

Buy$188.4K
Aug 21, 26

ADAR1 Capital Management, LLC

Indirect

Buy$1.3M

1–10 of 18

Summary

Insiders reported 18 buys worth $5.04M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $5.04M. ADAR1 Capital Management, LLC was the most active insider with 7 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Tenax Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about TENX's management, answered from reported figures.

Who manages TENX?

Tenax Therapeutics, Inc. (TENX) lists 8 active executives. The top listed executive is So-Young Kim, Executive Vice President of Clinical Development & Strategy.

Are TENX insiders buying or selling?

Recent insider activity shows net buying of $48.34M.